NCT05997615: Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
- State
- Under way
- Phase
- Phase 1
- People
- 347 planned
- Started
- 10 Aug 2023
- Primary completion
- 30 Sep 2027
- Arms
- Part 3a: VIR-5500 in Combination with an ARSI for Dose Escalation, Part 4a: VIR-5500 in Combination with an ARSI for Dose Expansion
- Results
- None posted
- 10 Aug 2023: Trial started
- 18 Aug 2023: Trial registered